Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Completed · Not applicable

Conditions studied: Assess Phenylephrine on EVP and IOP

In brief

Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris. Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non-invasively by venomanometry. Since phenylephrine is a vasoconstrictor, it may affect episcleral venous tone, but the effect on EVP is unknown. Understanding the physiology of episcleral veins helps us in better understanding of pathophysiology of glaucoma.

Key facts

Study ID

NCT02965924

Run by

Mayo Clinic

People needed

20

Starts

2016-10-01

Expected to finish

2018-10-01

Last updated by the study team

2019-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Any self-declared ethno-racial category.
• Medically healthy subjects.
• Subjects with two healthy eyes.
• Intraocular pressure (IOP) less than 22 mmHg in each eye.
• Best-corrected visual acuity (BCVA) in each eye 20/50 or better.
• Open angles in both eyes.
• Contact lens wear stopped at least 3 days prior to study, and during the study.
• Ability to cooperate for examinations required for study.

You may not qualify if…

• Chronic or acute ophthalmic diseases including glaucoma, wet type macular degeneration, uveitis and clinically significant cataract.
• Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis.
• Cornea pathologic changes preventing reliable measurement.
• Narrow anterior chamber angle.
• Previous intraocular surgeries, laser procedures, and intravitreal injections.
• Previous corneal refractive surgeries.
• Myopia greater than -6.00 D spherical equivalent.
• Hyperopia greater than +2.00 D spherical equivalent.
• Lack of suitable episcleral vein for measurement.
• Ocular trauma within the past 6 months.
• Ocular infection or ocular inflammation in the past 3 months.
• Ocular medication of any kind within 30 days of study visit.
• Known hypersensitivity to Phenylephrine or topical anesthetic medication.
• Severe hypertension: Systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 105 mmHg.
• A known history of ischemic heart disease (angina or myocardial infarction), cerebrovascular accidents, cardiac arrhythmias, cerebral or aortic aneurysms.
• Uncontrolled diabetes mellitus.
• Uncontrolled hyperthyroidism.
• Use of some systemic medications within 30 days prior to study including: β-adrenergic antagonists, α-adrenergic agonists and antagonists, calcium channel blockers, diuretics, vasodilators, monoamine oxidase inhibitors, and systemic steroids.
• Participation in any interventional study within the past 30 days prior to study visit.
• Women who are pregnant.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.